CryoTherapeutics is pioneering the use of cryotherapy as a novel approach to treat and prevent heart attacks by targeting atherosclerotic plaques in coronary arteries. The company has developed a patented catheter technology that delivers cryoenergy at temperatures between -10°C and -20°C directly to the affected areas. This method promotes arterial repair without the need for permanent implants, such as stents, which are commonly associated with complications like vessel re-narrowing. The CryoTherapeutics CTS system is designed to enhance the healing response of the vessel, potentially stabilizing high-risk plaques and reducing the risk of plaque rupture that can lead to heart attacks.

Preclinical studies have demonstrated the feasibility and effectiveness of this cryotherapy approach in stabilizing atherosclerotic plaques, as evidenced by changes in plaque composition observed in animal models. Research indicates that cryotherapy can elevate Type I collagen levels and reduce inflammation in treated areas, suggesting a shift towards a more stable plaque phenotype. The extensive medical experience with cryotherapy across various applications supports its safety and efficacy, particularly in cardiovascular contexts. By addressing the underlying pathophysiology of vulnerable plaques, CryoTherapeutics aims to provide a significant advancement in the treatment of atherosclerosis, offering a promising alternative to traditional interventional methods.

France

CryoTherapeutics is a company that focuses on developing cryotherapy systems for the treatment of heart attacks in Europe and the USA.

CryoTherapeutics

Company Details